Lumboperitoneal shunting of cerebrospinal fluid versus anti-tumor necrosis factor treatment of cauda equina syndrome in ankylosing spondylitis: comment on the article by Cornec et al.
Ea
Hang-Korng
HK
Lot
Guillaume
G
Bardin
Thomas
T
D000368:Aged; D002557:Cerebrospinal Fluid Shunts; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D011128:Polyradiculopathy / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000473:pathology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept